CytoSorbents: Q4 Earnings Insights
CytoSorbents (NASDAQ:CTSO) reported its Q4 earnings results on Tuesday, March 8, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
CytoSorbents Q4 EPS $(0.21) Misses $(0.13) Estimate, Sales $10.80M Beat $10.11M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 2000 percent decrease over losses of $(0.01) per share from the
Earnings Scheduled For March 8, 2022
Companies Reporting Before The Bell
• Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million.
CytoSorbents Earnings Preview
CytoSorbents (NASDAQ:CTSO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement.
Analysts estimate that CytoSorbents will report an earnings per share (EPS) of $-0.13.
CytoSorbents Corporation Announces First Patient Enrolled In The PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb To Restore Hemodynamic Stability In Patients With Refractory Septic Shock
CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption
CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds
CytoSorbents Corp (NASDAQ: CTSO) reported preliminary
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
28 Stocks Moving In Friday’s Mid-Day Session
Gainers
Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.